Sanofi: Undervalued 2026 Pipeline, And Solid Results (Rating Upgrade)

Group 1 - The article revisits Sanofi after a downgrade in early May 2024, which has been validated by market performance [1] - The S&P 500 has delivered double-digit returns since the downgrade, indicating a broader market trend [1] Group 2 - The analysis is conducted by buy-side hedge professionals focusing on fundamental, income-oriented, long-term analysis across global developed markets [1]